Make your money go further for just 25p per day

PREMIUM
AIM IHT

Big growth in human challenge trials

Virus in phial

This leader in the testing of infectious diseases using human challenge studies has issued another encouraging trading update. With a highly supportive order book, strong cash position and move to a larger and much improved facility, the future continues to look bright for our Stonking Small Cap.


Human Challenge Trials (HCTs), in which healthy volunteers are deliberately infected with a pathogen to study the course of a disease and the effectiveness of potential treatments, are a valuable tool for developing new vaccines and treatments for infectious diseases.

The fast-growing AIM company covered below is developing a leading position in HCTs and has recently announced excellent interim results. 

It provides end-to-end early clinical development services for a broad and long-standing client base of global…

Continue reading our content…

Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
  • Unlimited access to our market-beating portfolios
  • In-depth coverage of many of the world’s great companies
  • Unique insights from our top research team
Register FREE for access to limited content.
  • Company and markets insights
  • Sponsored content
  • Podcasts

Previous article Next article

DON'T MISS OUT!

Get top investment ideas to help safeguard and grow your wealth.

Invaluable insight from the exciting world of smaller companies.

REGISTER FREE

DON'T MISS OUT ON OUR PREMIUM CONTENT

Become a champion investor for just £90 a year. Benefit from our high performing portfolios:

START FREE TRIAL

More Company Insights

Bonkers Bargains: another great update

18/07/2024 · Alumasc Group PLC

Chain cheers | Interest winner | Meaty first

17/07/2024 · Agronomics · Gateley · Renold · Team17

Sign-up to our free email updates

SIGN UP